112
Participants
Start Date
July 31, 2007
Primary Completion Date
January 31, 2009
Study Completion Date
June 30, 2009
Trastuzumab emtansine [Kadcyla]
Trastuzumab emtansine was provided in either a liquid or a lyophilized formulation.
Eastchester Center/Cancer Care, The Bronx
New York Oncology Hematology, Albany
Washington Cancer Institute, Washington D.C.
Fairfax N Virginia Hem/Onc PC, Fairfax
Raleigh Hemotology & Oncology, Raleigh
Carolinas Hem-Oncology Assoc, Charlotte
Northwest Georgia Onc Ctrs PC, Marietta
Mayo Clinic, Jacksonville
Florida Cancer Care, Davie
Lynn Cancer Institute - West, Boca Raton
Bay Area Oncology, Tampa
Gulfcoast Oncology Associates, St. Petersburg
Hem/Onc Assoc - Treasure Coast, Port Saint Lucie
Kentuckiana Cancer Institute, Louisville
Cedar Valley Med Specialists, Waterloo
Minnesota Oncology Hematology,, Minneapolis
John McClean, M.D. - Private P, Galesburg
St. Louis Cancer & Breast Inst, St Louis
Kansas City Cancer Center, LLC, Lee's Summit
Missouri Cancer Associates, Columbia
Little Rock Hem Onc Assoc, Little Rock
US Oncology Research, Inc., Dallas
Sammons Cancer Center, Dallas
USO - Tyler Cancer Ctr, Tyler
Texas Oncology, P.A., Bedford
Texas Oncology PA, Fort Worth
Waco Cancer Care & Research Ce, Waco
Cancer Specialists of South Te, Corpus Christi
Texas Oncology Cancer Center, Austin
US Oncology, Midland
El Paso Cancer Treatment Ctr, El Paso
Rocky Mountain Cancer Center, Denver
Northern Utah Associates, Ogden
Northwest Medical Specialties, Tacoma
Northwest Cancer Specialists, Vancouver
St. Barnabas Health Care Sys, Livingston
Midwestern Regional Med Center, Eugene
USO, Dallas
Texas Oncology, P.A., Dallas
Texas Oncology, P.A., Houston
Lead Sponsor
Genentech, Inc.
INDUSTRY